Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Geographic Atrophy | 3 | 2023 | 23 | 2.390 |
Why?
|
| Visual Acuity | 7 | 2024 | 824 | 1.650 |
Why?
|
| Retinal Pigment Epithelium | 3 | 2023 | 35 | 1.630 |
Why?
|
| Refractive Errors | 2 | 2024 | 85 | 1.520 |
Why?
|
| Tomography, Optical Coherence | 6 | 2023 | 523 | 1.480 |
Why?
|
| Macular Degeneration | 2 | 2023 | 114 | 1.440 |
Why?
|
| Diabetic Retinopathy | 2 | 2024 | 157 | 1.370 |
Why?
|
| Wet Macular Degeneration | 4 | 2021 | 43 | 1.190 |
Why?
|
| Retinal Drusen | 2 | 2023 | 7 | 1.070 |
Why?
|
| Telemedicine | 2 | 2024 | 439 | 1.050 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 35 | 0.930 |
Why?
|
| Vision Screening | 1 | 2024 | 7 | 0.930 |
Why?
|
| Refraction, Ocular | 2 | 2024 | 306 | 0.920 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 63 | 0.910 |
Why?
|
| Vitreoretinal Surgery | 1 | 2023 | 8 | 0.870 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2023 | 208 | 0.870 |
Why?
|
| Subretinal Fluid | 1 | 2021 | 12 | 0.760 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 443 | 0.720 |
Why?
|
| Biological Factors | 1 | 2020 | 27 | 0.680 |
Why?
|
| Fluorescein Angiography | 4 | 2023 | 141 | 0.470 |
Why?
|
| Biomarkers | 1 | 2023 | 3064 | 0.460 |
Why?
|
| Vision Tests | 2 | 2024 | 38 | 0.400 |
Why?
|
| Multimodal Imaging | 2 | 2023 | 113 | 0.380 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2009 | 8 | 0.320 |
Why?
|
| Protein Phosphatase 2 | 1 | 2009 | 29 | 0.320 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 98 | 0.300 |
Why?
|
| src-Family Kinases | 1 | 2009 | 90 | 0.300 |
Why?
|
| Janus Kinase 2 | 2 | 2009 | 134 | 0.300 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2009 | 213 | 0.280 |
Why?
|
| Humans | 17 | 2024 | 124802 | 0.280 |
Why?
|
| Eyeglasses | 1 | 2024 | 14 | 0.230 |
Why?
|
| Intravitreal Injections | 2 | 2023 | 147 | 0.210 |
Why?
|
| Follow-Up Studies | 2 | 2023 | 5153 | 0.210 |
Why?
|
| Retinal Vein Occlusion | 1 | 2023 | 29 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2024 | 93 | 0.200 |
Why?
|
| Retrospective Studies | 5 | 2023 | 16290 | 0.200 |
Why?
|
| Disease Progression | 3 | 2023 | 2052 | 0.200 |
Why?
|
| Apoptosis | 1 | 2009 | 1792 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 511 | 0.190 |
Why?
|
| Uveitis | 1 | 2022 | 36 | 0.190 |
Why?
|
| Exudates and Transudates | 1 | 2021 | 22 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2021 | 410 | 0.180 |
Why?
|
| Internet | 1 | 2024 | 383 | 0.180 |
Why?
|
| Choroidal Neovascularization | 1 | 2021 | 29 | 0.180 |
Why?
|
| Vision Disorders | 1 | 2021 | 212 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2009 | 2610 | 0.150 |
Why?
|
| Aged | 2 | 2024 | 19693 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1272 | 0.120 |
Why?
|
| Middle Aged | 2 | 2024 | 26727 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2881 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2024 | 6138 | 0.110 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 6522 | 0.100 |
Why?
|
| Cyclohexanes | 1 | 2009 | 8 | 0.080 |
Why?
|
| Tyrphostins | 1 | 2009 | 14 | 0.080 |
Why?
|
| Histone Chaperones | 1 | 2009 | 11 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 44 | 0.080 |
Why?
|
| Male | 3 | 2024 | 61302 | 0.080 |
Why?
|
| Benzamides | 1 | 2009 | 106 | 0.080 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2007 | 5 | 0.070 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 94 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2007 | 41 | 0.070 |
Why?
|
| Female | 3 | 2024 | 66575 | 0.070 |
Why?
|
| Piperazines | 1 | 2009 | 238 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 488 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2009 | 372 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 1626 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 721 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 618 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12341 | 0.060 |
Why?
|
| Adult | 1 | 2024 | 29482 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 64 | 0.050 |
Why?
|
| Choroid | 1 | 2022 | 39 | 0.050 |
Why?
|
| Atrophy | 1 | 2021 | 235 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2000 | 13 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 30 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 2060 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2000 | 54 | 0.040 |
Why?
|
| Retina | 1 | 2023 | 453 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2000 | 339 | 0.030 |
Why?
|
| Cell Movement | 1 | 2000 | 835 | 0.030 |
Why?
|
| Mice | 2 | 2009 | 17757 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 1709 | 0.020 |
Why?
|
| Animals | 2 | 2009 | 34200 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 35 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2007 | 90 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 212 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 1069 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2007 | 891 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 2000 | 16 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 2000 | 15 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 4543 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2000 | 2825 | 0.010 |
Why?
|